Martinsried/Munich, 18 March 2014. Biotechnology company, Medigene AG (MDG1, Frankfurt, Prime Standard) has signed an exclusive global licence agreement with the company Dr. Falk Pharma GmbH (Falk Pharma) for the development and commercialization of its drug candidate RhuDex® for indications in hepatology and gastroenterology. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas. Medigene will receive an upfront payment and future milestone payments from Falk Pharma, plus double-digit RhuDex® royalties. Falk Pharma will initially concentrate on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in the indication areas rheumatoid arthritis, psoriasis and other autoimmune diseases.
Confidentiality was agreed on financial details of the deal. Medigene will provide the company's financial and operational guidance with the annual financial and operations report and conference call on 27 March 2014.
Further information on the RhuDex® licence agreement with Falk Pharma is provided with today's press release of Medigene AG at www.medigene.com.
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to: www.medigene.de/unsubscribe